Table 2.

Summary of epoetin, hemoglobin, transferrin saturation, and serum ferritin throughout DRIVE and DRIVE-II stratified by baseline serum ferritin

Baseline Ferritin StratumControlIV Ferric Gluconate
BaselineEnd of DRIVEEnd of DRIVE-IIBaselineEnd of DRIVEEnd of DRIVE-II
≤800 ng/ml
    n3334
    epoetin dose, IU/kg per wk543 ± 329679 ± 411671 ± 451438 ± 253548 ± 317445 ± 281
    Hb, g/dl10.2 ± 0.711.4 ± 1.111.5 ± 1.110.3 ± 0.911.9 ± 1.412.0 ± 1.4
    TSAT, %a18.7 ± 3.619.9 ± 6.417.6 ± 6.218.7 ± 3.625.5 ± 6.123.7 ± 12.8
    serum ferritin, ng/mla631 ± 86453 ± 172506 ± 274622 ± 89798 ± 184698 ± 179
> 800 ng/ml
    n2322
    epoetin dose; IU/kg per wk466 ± 216582 ± 271605 ± 346480 ± 207600 ± 257500 ± 354
    Hb, g/dl10.1 ± 0.811.4 ± 1.611.7 ± 1.810.3 ± 0.712.0 ± 1.312.3 ± 1.3
    TSAT, %b19.6 ± 4.522.5 ± 4.621.9 ± 6.317.5 ± 4.826.4 ± 8.625.9 ± 18.3
    serum ferritin, ng/mlb923 ± 135762 ± 292717 ± 278968 ± 1221139 ± 288995 ± 345
  • Hb, hemoglobin; TSAT, transferrin saturation.

  • a Based on 31 patients in the control group and 33 patients in the IV ferric gluconate group.

  • b Based on 22 patients in each treatment group.